NCT06313944Recruiting
German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation
German (GE) Multicenter Prospective Data Collection (Registry) on Treatment With Transcranial Pulse Wave Stimulation (TPS) in Patients With Alzheimer's Disease (A)
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market Clinical Follow-up). The multicenter, prospective data collection should help to optimize the stimulation protocol, as well as to record frequent to occasional adverse effects of the product and cognitive, affective and subjective scores.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 8 Mar 2024
- Start date
- 6 Aug 2025
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- Heinrich-Heine University, Duesseldorf
- Diseases
- Alzheimer disease
- NCT number
- NCT06313944
What you commit to
- Study type: Observational
- Planned participants: 100
- From 6 Aug 2025 to the primary completion date, 1 Oct 2027
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Relevant intracerebral pathologies not related to Alzheimer's disease, such as vascular encephalopathy Fazekas grade 3, tumors, vascular malformations, pregnancy, metal implants, CAA according to Boston criteria, Z.n. or during antibody therapy ii. Blood coagulation disorders or oral anticoagulation iii. Epilepsy iv. Medical conditions leading to non-compliance with the protocol
Who the study is looking for
- Age = 18 to 85 ii. N\>=100, clinical Alzheimer's syndrome, defined by a gradually progressive change in memory function (for severity using the MMSE as a screening tool) and impairment of activities of daily living for more than six months iii. MRI scan, in vivo evidence from CSF and/or PET using the NIA-AA criteria, which categorize the underlying pathological processes based on biomarkers, should be added if possible, but are optional. These biomarkers are categorized as ß-amyloid deposition, pathological tau and neurodegeneration \[AT(N)\], which can be detected on imaging and in biofluids. If possible, patients with Alzheimer's disease (AD) or Alzheimer's continuum should be included.
- TPS treatment in a center of a neurological or psychiatric specialist and performed under supervision of a specialist
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitätsklinikum Bonn - Klinik für Parkinson, Schlaf- und Bewegungsstörungen Coordinator of this site? Confirm its status | Bonn | Germany | Not yet recruiting |
| Hospital zum Heiligen Geist GmbH & Co KG Klinik für Neurologie und Neurorehabilitation Coordinator of this site? Confirm its status | Kempen | Germany | Withdrawn |
| Neurologische Praxis Prof. Wojtecki Coordinator of this site? Confirm its status | Neuss | Germany | Recruiting |
| Evangelische Krankenhausstiftung Oldenburg - Universitätsklinik für Neurologie Coordinator of this site? Confirm its status | Oldenburg | Germany | Recruiting |
| Ernst von Bergmann Klinikum - Klinik für Neurologie und Klinische Neuropsychologie Coordinator of this site? Confirm its status | Potsdam | Germany | Recruiting |
| Praxis Dr. Schwarz Coordinator of this site? Confirm its status | Ulm | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.